Monday, October 3, 2016

Carbalax Suppositories





1. Name Of The Medicinal Product



CARBALAX SUPPOSITORIES


2. Qualitative And Quantitative Composition



Each suppository contains:



Sodium acid phosphate anhydrous 1.3g



(equivalent to Sodium Acid Phosphate Ph Eur 1.69g)



Sodium Bicarbonate Ph.Eur. 1.08g



3. Pharmaceutical Form



Suppository for rectal administration



4. Clinical Particulars



4.1 Therapeutic Indications



Chronic simple constipation. Constipation due to prolonged bed-rest or to drugs. Bowel evacuation before childbirth, surgery, sigmoidoscopy, radiological examination and post- operatively. To avoid discomfort associated with straining. To regularise bowel movement and keep stools to normal consistency in local anal conditions such as haemorrhoids, fissures and fistulae.



4.2 Posology And Method Of Administration



Adults and the Elderly:



Administer one suppository 30 minutes before evacuation is required.



Children under 12:



Not recommended.



4.3 Contraindications



Conditions where any bowel medication for the relief of constipation is contra-indicated.



4.4 Special Warnings And Precautions For Use



The suppository should be moistened with water, not lubricated with oil before insertion.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



None known



4.6 Pregnancy And Lactation



No restriction



4.7 Effects On Ability To Drive And Use Machines



None known



4.8 Undesirable Effects



Side effects are unlikely.



4.9 Overdose



Overdose has not been reported.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Carbalax Suppositories function by a physical induction of reflex bowel evacuation caused when carbon dioxide is liberated when the suppository contacts moisture. Bowel action will usually take place within half an hour after administration.



5.2 Pharmacokinetic Properties



If any bicarbonate is not converted to carbon dioxide it may be absorbed and excreted as bicarbonate ions in the urine. Any absorbed phosphate will also eventually be excreted in the urine.



5.3 Preclinical Safety Data



There are no preclinical data of relevance to the prescriber that might add to the safety data provided in other sections of this SPC.



6. Pharmaceutical Particulars



6.1 List Of Excipients



Polyethylene glycol 1500



6.2 Incompatibilities



None stated



6.3 Shelf Life



One year



6.4 Special Precautions For Storage



Store below 25oC in a dry place.



6.5 Nature And Contents Of Container



Each suppository is contained in a PVC shell. The shells are supplied in strips of 12 in a cardboard carton of 12 or 60 suppositories.



6.6 Special Precautions For Disposal And Other Handling



None stated



7. Marketing Authorisation Holder








Forest Laboratories UK Limited




Bourne Road




Bexley




Kent DA5 1NX



8. Marketing Authorisation Number(S)



PL 0108/5001R



9. Date Of First Authorisation/Renewal Of The Authorisation



2 May 1990 / 22 September 1997



10. Date Of Revision Of The Text



July 1997



11. Legal Category


GSL




No comments:

Post a Comment